Evidence Hub

Commentary: effect of flavonoids on normal and leukemic cells

Faderl S, Estrov Z

Leukemia research, 2003

Abstract

The success of the phosphotyrosine kinase inhibitor imatinib mesylate (STI571, Gleevec has emphasized the significance of a growing understanding of tumor cell biology. The search has since been intensified to identify other candidate molecules in cancer cell-specific signaling transduction pathways whose disruption may result in similar therapeutic benefits. Flavonoids are potent inhibitors of cyclin-dependent kinases, but in addition also inhibit the activity of angiogenic mediators and induce apoptosis by mechanisms that are still not fully understand. In the current study by Liesveld et al., flavonoids are shown to have an antiproliferative and proapoptotic effect in leukemic cells. The implications of the results of this study on the activity of flavonoids in leukemias and their future development are being discussed.

How strong is the evidence?

Evidence Hub reads this as a editorial / letter, done in cell cultures (in vitro), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free